Overview
Lymphangiosarcoma is a rare malignant neoplasm originating from lymphatic endothelial cells, characterized by abnormal proliferation and replacement of subcutaneous tissue with arborizing vascular channels lined by pleomorphic cells. It closely mimics hemangiosarcoma histologically but differs clinically and in treatment requirements. 1Diagnosis
Histopathological Features: Arborising vascular channels lined by pleomorphic endothelial cells with scant erythrocytes.
Immunohistochemical Markers: Use of lymphatic vessel endothelial receptor-1 (LYVE-1) and prospero-related homeobox gene-1 (PROX-1) to differentiate from hemangiosarcoma.
Traditional Markers: Factor VIII-related antigen (F8RA) and CD31 lack specificity for lymphatic vs. blood endothelial origin.Management
Surgical Resection: Primary treatment when feasible, aiming for complete removal.
Adjuvant Therapy: Limited evidence; may include chemotherapy or radiation depending on extent and invasiveness.
Supportive Care: Focus on symptom management and palliative care for advanced cases.Special Populations
No Specific Guidance: Abstracts do not provide specific management recommendations for pregnancy, pediatrics, elderly, or comorbid conditions. 1Key Recommendations
Utilize LYVE-1 and PROX-1 immunohistochemical markers to accurately differentiate lymphangiosarcoma from hemangiosarcoma in diagnostic workup. (Evidence: Moderate) 1
Prioritize surgical resection as the primary treatment modality when feasible. (Evidence: Expert opinion) 1
Consider adjuvant therapies cautiously based on tumor stage and patient condition, given limited evidence supporting specific regimens. (Evidence: Weak) 1References
1 Halsey CH, Worley DR, Curran K, Charles JB, Ehrhart EJ. The use of novel lymphatic endothelial cell-specific immunohistochemical markers to differentiate cutaneous angiosarcomas in dogs. Veterinary and comparative oncology 2016. link